Various Symptoms, Prevention and Treatments of Corona-virus (Covid-19)

Authors

  • Amol G. Jadhao Department of Pharmaceutics, Gawande College of Pharmacy, Sakharkherda, Buldana, Maharastra, India
  • Vaishali B. Magar Department of Pharmaceutics, Gawande College of Pharmacy, Sakharkherda, Buldana, Maharastra, India

DOI:

https://doi.org/10.22270/ajprd.v9i6.1028

Keywords:

Remdesivir, Favipiravir, Coronavirus, SARS-CoV-2, COVID-19, Convalescent plasma, Monoclonal Antibodies.

Abstract

Corona means “crown,” and examined nearly, the round virus has a “crown” of  proteins called peplomers jutting out from its center in every direction. These proteins help the virus identify whether it can infect its host. The severe acute respiratory syndrome has caused an alarmimg situation of the worldwide. The first detection, in Decmber2019, there have been no effective drug therapy options for treating the SARS-CoV-2 pandemic. And healthcare professionals are using some drug like remdesivir, favipiravir, chloroquine, hydrochloroquine, azithromycin, paracetamol, steroids, multivitamins, ivermectin, tocilumab, NSAIDs, treatment with monoclonal antibodies and convalescent plasma etc. of treatments. The condition known as severe acute respiratory syndrome (SARS) was also linked to a highly infectious coronavirus. The SARS virus has since been included and found to be successfully curable. The disease is caused by the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2), previously referred to as the 2019 novel coronavirus (2019-nCoV). The symptoms  is typically rapid, ranging from hours to days after infection. Symptoms include fever, cough and, often, sore throat, headache, Sneezing, shortness of breath, wheezing, or difficulty in breathing.  Reduce their anxiety level effectively when they are in the events of stress by using reasonable coping styles. Early studies of the out-break focused on the novel coronavirus gene and structure modeling, host and clinical case analysis. Currently, hundreds of registered clinical trials are underway, most of which are assessing antiretroviral agents, anti-inflammatory or immunosuppressant therapies, and passive antibody treatments.

 

Downloads

Download data is not yet available.

Author Biographies

Amol G. Jadhao, Department of Pharmaceutics, Gawande College of Pharmacy, Sakharkherda, Buldana, Maharastra, India

Department of Pharmaceutics, Gawande College of Pharmacy, Sakharkherda, Buldana, Maharastra, India

Vaishali B. Magar, Department of Pharmaceutics, Gawande College of Pharmacy, Sakharkherda, Buldana, Maharastra, India

Department of Pharmaceutics, Gawande College of Pharmacy, Sakharkherda, Buldana, Maharastra, India

References

1. Walid Al-Zyoud, Thelal Oweis , Haytham Al-Thawabih The Psychological Effects of Physicians’ Communication Skills on COVID-19 Patients, in Dovepress research, patient Preference and Adherence 2021:15 677–690.
2. Nirav Nimava, Shruti Singh, et al Online Medical Education in India – Different Challenges and Probable Solutions in the Age of COVID-19, in Dovepress research, advances in Medical Education and Practice 2021:12 237–243.
3. Eric Salazar, y Paul A. et al. Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality, in Elsevier, Immunopathology And Infectious Diseases The American Journal of Pathology, 2020; 190(11).
4. Wantong Han1, Lingzhong Xu1, Aimin Niu, Online-Based Survey on College Students’ Anxiety During COVID-19 Outbreak in Dovepress reaearsch, Psychology Research and Behavior Management 2021; 14 385–392.
5. Carlos Chaccoura, Aina Casellasa, Andres Blanco-Di Matteo, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial in Elsevier, 2589-5370/© 2021.
6. Infection prevention and control of epidemic- and pandemic-prone acute respiratory infections in health care, WHO Guidelines epidemic and pandemic diseases, Infection prevention and control of epidemic- and pandemic-prone acute respiratory infections page no. XIV.
7. Sultan Ayoub Meo, Syed Ziauddin A. Zaidi, Trisha Shang,et al. Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis, Journal of King Saud University – Science 32, 2020; 3159–3166.
8. Mukhtar H. Ahmed1 & Arez Hassan, Dexamethasone for the Treatment of Coronavirus Disease (COVID-19) : a Review, COVID-19, SN Comprehensive Clinical Medicine.
9. Duaa Mohamed Bakhshwin1 and Abdulaziz Bakhshwin, Impact of the Emerging COVID-19 Pandemic on the Consumption of Multivitamins (C, D and Zinc) by the Saudi Arabian Population, Journal of Pharmaceutical Research International, 33(26B): 11-20, 2021;Article no.JPRI.67426ISSN: 2456-9119.
10. Nuno Santos Leal, Yizhow Yu, Yuwen chen, Giogio Fedele and Luis Miguel Martins, Paracetamol Is Associated with a Lower Risk of COVID-19 Infection and Decreased ACE2 Protein Expression: A Retrospective Analysis,COVID 2021, 1(1),218229; https://doi.org/10.3390/covid1010018.
11. Hydroxychloroquine in the prevention of COVID-19 mortality Published Online November 5, 2020 https://doi.org/10.1016/ S2665-9913(20)30390-8 See Articles,2021; 31:9.
12. Daniel Adane1 Alex Yeshaneh 1 Biresaw Wassihun 2 Addisu Gasheneit3, Level of Community Readiness for the Prevention of COVID-19 Pandemic and Associated Factors Among Residents of Awi Zone, Ethiopia: A Community-Based Cross-Sectional Study in Dovepress, Risk Management and Healthcare Policy, 2021:14 1509–1524.
13. Sören Jeppesen & Jason Miklian, Introduction: Research in the Time of Covid-19, Forum for Development, Routledge Taylor and francies group, 2020; 47(2):207–217,
14. Tim Smith, PharmD, BCPS; Jennifer Bushek, PharmD; Aimée LeClaire, PharmD, BCPS; Tony Prosser, PharmD, COVID-19 Drug Therapy by Clinical Drug Information Clinical Solutions Elsevier publication, Updated October 23, 2020.
15. Leila Jahanshahlua, Nima Rezaeic, Monoclonal antibody as a potential anti-COVID-19, Biomedicine & Pharmacotherapy, https://doi.org/10.1016/j.biopha.2020.110337.
16. Gopala Koneru, Gaber El-Saber Batiha, Abdelazeem M Algammal, et al BCG Vaccine-Induced Trained Immunity and COVID-19: Protective or Bystander? Infection and Drug Resistance from Dovepress, 2021:14 1169–1184.
17. Serena Capici,Luca Sala, Stefania Galimberti,et al The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data, Infection, rapid communication from Dovepress, Infection and Drug Resistance 2021:14 1389–1392.
18. Temesgen Yihunie Akalu, Kassahun Alemu Gelaye, Mulat Addis Bishaw, Depression, Anxiety, and Stress Symptoms and Its Associated Factors Among Residents of Gondar Town During the Early Stage of COVID-19 Pandemic, , from Dovepress, Risk Management and Healthcare Policy 2021:14 1073–1083.
19. P. BrouquiA. Giraud-Gatineau D. Raou, Critical reappraisal of remdesivir investigational trials in COVID-19, New Microbes and New Infections, A mini review, 2020; 38(11).
20. Sanders JM, Monogue ML,Jodlowski TZ,Cutrell JB, Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) A Review of JAMA, 01 May 2020; 323(18):1824-1836.
21. Mohamed Adam, Moawia Gameraddin, Magbool Alelyani, Assessment of Knowledge, Attitude, and Practice Concerning COVID-19 Among Undergraduate Students of Faculty of Applied Medical Sciences at King Khalid University, Abha, Kingdom of Saudi Arabia: A Cross-Sectional Surveyed Study, Advances in Medical Education and Practice 2021:12 789–797.
22. Dalia Tohamy, Mohamed Sharaf, Khaled Abdelazeem, A Research paper of Ocular Manifestations of Post-Acute COVID-19 Syndrome, Upper Egypt Early Report, Journal of Multidisciplinary Healthcare 2021:14 1935–1944.
23. Eric William Hall ; Nicole Luisi ; Maria Zlotorzynska ;Willingness to Use Home Collection Methods to Provide Specimens for SARS-CoV-2/COVID-19 Research: Survey Study, Journal of Medical Internet Research, 2020 Sep; 22(9): e19471, Published online 2020 Sep 3. doi: 10.2196/19471, PMCID: PMC7473702, PMID: 32790639.
24. Deepak Garg . Valliappan Muthu . Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature, https://doi.org/10.1007/s11046-021-00528-2(0123456789().,-volV)(01234567.

Published

2021-12-15

How to Cite

Jadhao, A. G., & Magar, V. B. (2021). Various Symptoms, Prevention and Treatments of Corona-virus (Covid-19). Asian Journal of Pharmaceutical Research and Development, 9(6), 90–97. https://doi.org/10.22270/ajprd.v9i6.1028

Most read articles by the same author(s)